{
    "ucits": true,
    "type": "ETP",
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": false,
    "replication_method": "synthetic",
    "complex_factors": "Leverage, Synthetic replication, Derivatives, Compounding effect, Structured product features",
    "classification": "complex",
    "supporting_data": "The product is a 3x leveraged Exchange Traded Product (ETP) that seeks to provide three times the daily performance of the ARK Innovation ETF, indicating significant leverage and use of derivatives. The product uses collateralized securities and margin accounts, implying synthetic replication and derivative exposure (swaps or similar instruments) to achieve the leveraged exposure. The daily rebalancing and compounding effect introduce complexity in understanding returns over periods longer than one day. The product is explicitly described as not simple and difficult to understand, with a high risk indicator (7/7), and is intended for sophisticated investors able to monitor frequently and understand leverage and compounding risks. The use of derivatives is integral to the investment strategy, not merely for efficient portfolio management, and the leverage is significant (3x), which under MiFID II rules and ESMA guidance classifies the product as complex. The product does not have capital protection and involves counterparty and collateral risks inherent in synthetic replication. According to MiFID II Article 25(4)(a)(vi) and Article 57 of the Delegated Regulation, such features (leverage, synthetic replication, embedded derivatives) make the product complex, requiring an appropriateness assessment for retail investors. This aligns with ESMA and CESR guidance that leveraged ETFs, synthetic ETFs, and products with embedded derivatives or complex payoff structures are complex. Therefore, despite being UCITS-compliant in form, the product's structure and risk profile classify it as complex under MiFID II."
}